2025
Glucarpidase for treatment of high-dose methotrexate toxicity
Gupta S, Kaunfer S, Chen K, Dias J, Vijayan A, Rajasekaran A, Prosek J, Truong H, Wood A, Bassil C, Renaghan A, Shah C, Zhang J, Glezerman I, Carlos C, Kelly K, Passero C, Drappatz J, Abudayyeh A, Shin D, Sperati C, Yelvington B, Kanduri S, Neyra J, Edmonston D, Shirali A, Bansal A, Geara A, Mithani Z, Ziolkowski S, Rashidi A, Jakubowski J, Pujari A, Bond D, Dotson E, Wall S, Patton J, Barreto J, Herrmann S, Sheikh M, Baz R, Lee J, Lucchesi N, Kolman M, Rasheed M, Afzal A, Kang D, Mahesh A, Hsu R, Nicolaysen A, Tefera K, Schretlen C, Miller R, Velez J, Flannery A, Aklilu A, Anand S, Chandrasekhara S, Donley V, Patel A, Ni J, Krishnamurthy S, Ali R, Yilmam O, Wells S, Ortega J, Green-Lingren O, Leaf R, Sise M, Nayak L, LaCasce A, Leung N, Leaf D. Glucarpidase for treatment of high-dose methotrexate toxicity. Blood 2025, 145: 1858-1869. PMID: 39760780, DOI: 10.1182/blood.2024026211.Peer-Reviewed Original ResearchAcute kidney injuryHigh-dose methotrexate toxicityKidney recoveryPatients treated with glucarpidaseRates of acute kidney injuryDay 7Time to deathHigh-dose methotrexateCox regression modelsGlucarpidase administrationDialysis-dependentMethotrexate toxicityMethotrexate initiationKidney injuryClinical dataGlucarpidaseCancer CenterNeutropeniaEnd pointsMethotrexatePatientsHospital dischargeOutcomesTarget trial emulation frameworkDays
2023
Onco-Nephrology Kidney Disease in the Cancer Patient
Yarandi N, Shirali A. Onco-Nephrology Kidney Disease in the Cancer Patient. 2023, 107: 749-762. PMID: 37258012, DOI: 10.1016/j.mcna.2023.03.007.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseAcute kidney injuryChronic kidney diseaseDifferent clinical manifestationsSubspecialty of nephrologyOnco-NephrologyKidney injuryElectrolyte disturbancesClinical manifestationsCancer patientsGeneral internistsPatientsDiseaseCancerHypertensionProteinuriaInternistsInjuryNephrology
2022
Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY
Shirali AC. Is Rechallenge Appropriate in Patients that Develop Immune Checkpoint Inhibitor-Associated AKI?: COMMENTARY. Kidney360 2022, 3: 806-808. PMID: 36129422, PMCID: PMC9438420, DOI: 10.34067/kid.0005592021.Commentaries, Editorials and LettersCancer Drug Dosing in Chronic Kidney Disease and Dialysis
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Advances In Kidney Disease And Health 2022, 29: 208-216.e1. PMID: 35817528, DOI: 10.1053/j.ackd.2021.12.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseKidney functionEnd-stage kidney diseasePatient's kidney functionRenal replacement therapyCurrent dosing strategiesClassic chemotherapeutic drugsReplacement therapyDosing strategiesHigh prevalenceDrug dosingKidney metabolismAntineoplastic agentsPharmacokinetic propertiesChemotherapeutic drugsDiseaseSpecific agentsPatientsDosingTherapyDrugsAgentsImmunotherapyMalignancy
2021
Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome
Quraishi IH, Szekely AM, Shirali AC, Mistry PK, Hirsch LJ. Miglustat Therapy for SCARB2-Associated Action Myoclonus–Renal Failure Syndrome. Neurology Genetics 2021, 7: e614. PMID: 34337151, PMCID: PMC8320328, DOI: 10.1212/nxg.0000000000000614.Peer-Reviewed Original ResearchAction myoclonus-renal failure syndromeNeurologic symptomsAction myoclonusFailure syndromeProgressive myoclonic epilepsySubstrate reduction therapyWhole-exome sequencingMiglustat therapyAvailable medicationsEarly mortalityReduction therapyMyoclonic epilepsySteady worseningGaucher diseaseMyoclonusGlycosphingolipid metabolismExome sequencingGene mutationsGlucosylceramide accumulationPatientsSeizuresMiglustatSyndromeTherapySymptomsLysozyme nephropathy: A rare and reversible cause of acute kidney injury in chronic myelomonocytic leukemia
Donati A, Luciano R, Shirali A. Lysozyme nephropathy: A rare and reversible cause of acute kidney injury in chronic myelomonocytic leukemia. Journal Of Onco-Nephrology 2021, 5: 120-121. DOI: 10.1177/23993693211026926.Peer-Reviewed Case Reports and Technical Notes
2016
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal Of Kidney Diseases 2016, 68: 287-291. PMID: 27113507, DOI: 10.1053/j.ajkd.2016.02.057.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisPD-1 inhibitor therapyInhibitor therapyInterstitial nephritisLung cancerNon-small cell lung cancerAnti-PD-1 antibodyAcute kidney injuryImmune checkpoint inhibitorsT cell immunityCell lung cancerLung cancer patientsClinical trial dataRenal toleranceCheckpoint inhibitorsKidney injuryDeath-1Kidney biopsyCancer patientsPatientsTrial dataTherapyAdverse effectsDrugsNephritis
1998
Acid-base Homeostasis in Children With Growth Hormone Deficiency
Glaser N, Shirali A, Styne D, Jones K. Acid-base Homeostasis in Children With Growth Hormone Deficiency. 1998, 102: 1407-1414. PMID: 9832577, DOI: 10.1542/peds.102.6.1407.Peer-Reviewed Original ResearchConceptsMean serum bicarbonate concentrationSerum bicarbonate concentrationGrowth hormone deficiencyStandard deviation scoreGH treatmentShort statureGrowth hormoneAcid-base homeostasisHormone deficiencyBicarbonate concentrationLower serum bicarbonate concentrationMild metabolic acidosisSerum electrolyte concentrationsNormal acid-base homeostasisCause of acidosisRenal functionUnclear etiologyMetabolic acidosisMedical recordsOverall prevalenceGrowth failureDeviation scoreStudy populationPatientsIntermediate probability
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply